News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Zeltia Group Says in Advanced Talks to License Aplidin
October 24, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
MADRID, Oct 24 (Reuters) -Spanish biotechnology firm Zeltia is in advanced talks to license Aplidin in the United States and the rest of the world, with the exception of Europe, where it will license the drug on its own, the company said on Friday.
Twitter
LinkedIn
Facebook
Email
Print
Alliances
Europe
MORE ON THIS TOPIC
Alzheimer’s disease
Korsana Joins Alzheimer’s Amyloid Arena With $150M Debut, Next-Gen Antibody
February 18, 2026
·
2 min read
·
Tristan Manalac
Layoff Tracker
Concerto Downsizes Amid Pivot to Consumers; Faraday Closes Down
February 18, 2026
·
55 min read
·
BioSpace Editorial Staff
Podcast
Modernagate Fallout, Disc’s Rejection, Compass’ Psilocybin Data, CDC’s Lost Leaders
February 18, 2026
·
1 min read
·
Heather McKenzie
Patents
Proliferating Patents, Lawsuits Stave Off Pharmas’ Generic Competitors
February 18, 2026
·
4 min read
·
Shawna Williams
